Navigation Links
Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
Date:8/6/2008

Toronto Stock Exchange Symbol: DND

MISSISSAUGA, ON, Aug. 6 /PRNewswire-FirstCall/ - Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that it has entered into a definitive development, distribution and supply agreement with Ranbaxy Pharmaceuticals Inc. ("RPI"), a wholly owned subsidiary of Ranbaxy Laboratories Limited, under which Cipher has granted RPI the exclusive right to market, sell and distribute CIP-ISOTRETINOIN in the United States, its territories and possessions.

CIP-ISOTRETINOIN is a novel, patented formulation of isotretinoin, which is used in the treatment of severe nodular acne. The product received approvable letters from the U.S. Food and Drug Administration ("FDA") in May 2006 and April 2007 in which the FDA requested that Cipher provide additional clinical safety data. Cipher and its advisors are currently in discussions with the FDA's Division of Dermatology and Dental Products regarding the appropriate design of a safety study.

Under the terms of the agreement with RPI, Cipher received an initial upfront milestone payment of US$1 million. The agreement includes additional pre- and post-commercialization milestone payments of up to US$23 million, contingent upon the achievement of certain milestone targets. Once the product is successfully commercialized, Cipher will also receive a royalty in the mid-teens on net sales. In addition, RPI will reimburse Cipher for all costs associated with the clinical studies required to obtain FDA approval, up to a predetermined cap. Any additional development costs associated with initial FDA approval will be shared equally. Cipher is responsible for all product development activities, including management of the clinical studies required by the FDA to secure NDA approval. Cipher is also responsible for product supply and manufacturing, which would be fulfilled by its partner, Galephar Pharmaceutical Research. After product-related expenses are deducte
'/>"/>

SOURCE Cipher Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Ciphers revised NDA for CIP-TRAMADOL ER accepted for review by FDA
2. Cipher provides regulatory update for CIP-TRAMADOL ER
3. Cipher provides CIP-TRAMADOL ER regulatory update
4. Cipher appoints Stefan Aigner to board of directors
5. Cipher Appeals FDAs Decision On CIP-TRAMADOL ER
6. Cipher reports third quarter fiscal 2007 results
7. Pacira Pharmaceuticals, Inc. Adds Experienced CFO James S. Scibetta to Leadership of the Organization
8. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
9. Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results
10. Handa Pharmaceuticals Announces Submission of its First-to-File ANDA for AstraZenecas SEROQUEL(R) XR
11. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Washington, DC (PRWEB) August 01, 2014 ... approach offer health plans and employers effective options ... of narrow networks argue that they can enhance ... and administrative fees. Consultants report that nearly all ... responding to requests for proposals. The Aug. ...
(Date:8/1/2014)... Santa Clara, CA (PRWEB) August 01, 2014 ... the availability of EspressReport ES-AMI on AWS Marketplace. ... cloud, with subscriptions starting at $0.50 per hour ... a feature-rich, powerful yet easy-to-use enterprise BI and ... dashboard publishing, visual analytics and ad hoc reporting. ...
(Date:8/1/2014)... iFitDress.com, a professional company of women’s ... of 2014 silver bridesmaid dresses recently. All ... the latest fashion trends. What’s more, they are now ... off. , iFitDress.com is one of the leading ... only silver bridesmaid gowns, but also many other kinds ...
(Date:7/31/2014)... have asthma, you may have an asthma action plan with ... to changes and understand when symptoms are getting worse and ... doing well, yellow means your asthma has worsened and action ... guidelines are now available to help your allergist steer you ... from the red zone. , "Management of acute loss of ...
(Date:7/31/2014)... Leelanau Peninsula’s newest winery, Aurora Cellars ... 7788 East Horn Road in Lake Leelanau. Joining the Northern ... Cellars is the 25th winery along the trail. The winery ... tour events, making its trail event debut during the Harvest ... Owners David and Faye Mathia opened the boutique winery in ...
Breaking Medicine News(10 mins):Health News:Atlantic Information Services Webinar to Offer Health Plan, Employer Strategies for Implementing Narrow Pharma Networks 2Health News:Quadbase Systems Inc. Announces The Availability Of It’s Flagship Enterprise Reporting, Dashboard and BI Analytics Tool on Amazon’s AWS Marketplace 2Health News:iFitDress.com: Beautiful Silver Bridesmaid Dresses at Promotional Prices 2Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2
... A consortium of federal agencies and nongovernmental organizations has ... and data-collection methods for use in asthma clinical research. ... Outcomes Workshop, which appears as a supplement to the ... and Clinical Immunology , resulted from a meeting organized ...
... FRIDAY, March 2 (HealthDay News) -- Women become less likely ... first year of college, new research finds. Declining condom ... had worse grades and who came from poorer backgrounds. ... unplanned pregnancies and sexually transmitted diseases, yet there has been ...
... people who consume drugs containing cannabinoid compounds found in ... Marsicano (Inserm Research Unit 862) in collaboration with a ... mechanism by which these substances affect working memory. These ... adverse effect of cannabinoids on working memory is exerted ...
... in childhood have a higher risk of infertility in ... Balcerek and her co-authors in a study published in ... 109[7] 126-31). , In a nationwide German survey on ... the authors collected data from former pediatric oncology patients. ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, March ... to screen for cervical cancer are more likely to survive ... Swedish study suggests. Compared to women whose cervical cancer ... Pap smear increased their cure rate from 66 percent to ...
... news for the 27,000 plus people around the world who ... living kidney donors for 10 years found that they were ... general population. Led by Dr. Amit Garg, ... London Health Sciences Centre, the results provide important safety reassurances ...
Cached Medicine News:Health News:Standardized outcome measures proposed for asthma clinical research 2Health News:College Women's Condom Use Falls During Freshman Year 2Health News:How does cannabis affect working memory? 2Health News:How does cannabis affect working memory? 3Health News:Regular Pap Smear Boosts Cervical Cancer Survival: Study 2Health News:Regular Pap Smear Boosts Cervical Cancer Survival: Study 3Health News:First study of its kind finds no increased risk of heart disease for kidney donors 2
(Date:7/31/2014)... Surgical Company (NASDAQ: STAA ) a leading ... systems for the eye today reported revenue for the ... a 10% increase over $18.2 million reported for the ... revenues grew 11% during the second quarter of 2014 ... of foreign currency exchange reduced sales by $0.1 million ...
(Date:7/31/2014)... Xencor Inc. (NASDAQ: XNCR ), a ... the treatment of autoimmune diseases, asthma and allergic ... the second quarter ended June 30, 2014 and provided ... "In the second quarter, we presented preclinical data ... (ATS) demonstrating three novel mechanisms of action of ...
(Date:7/31/2014)... VIEW, Calif. , July 31, 2014 /PRNewswire/ ... today provided an update on its pipeline and ... 2014, Alexza expects to initiate a Phase 2a ... is being developed for the management of patients ... two new Staccato -based product candidates for ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6
... Wash., Feb. 21, 2011 Royal Philips Electronics NV ... MSFT ) today announced the companies will collaborate ... to build and understand the complete clinical context of ... commitment to work together to connect technologies that will ...
... Medical, Inc. (Nasdaq: NXTM ), a leading ... recent independent study which reports that home hemodialysis with ... carbon footprint of therapy conducted with traditional in-center hemodialysis ... delivering superior clinical results is a core competency of ...
Cached Medicine Technology:Philips and Microsoft Collaborate to Streamline Radiology Workflow and Processes 2Philips and Microsoft Collaborate to Streamline Radiology Workflow and Processes 3Independent Study Reports 50% Smaller Carbon Footprint With NxStage System One™ vs. Standard In-Center Hemodialysis Machines 2Independent Study Reports 50% Smaller Carbon Footprint With NxStage System One™ vs. Standard In-Center Hemodialysis Machines 3
The CGPL capsulotomy contact glass was designed by Riquin, Fankhauser et al. for the dissection of opacified posterior lens capsules and membranes in the pupillary and retropupillary space with the Y...
The CGAL gonioscopic contact glass was designed by Roussel and Fankhauser for,laser treatments of the chamber angle. It reduces the laser spot by a factor of 1.5 as compared to a Goldmann Glass....
The CGRL is a Wide Angle Contact Glass designed for laser photocoagulation and diagnosis of the retina....
The classic Goldmann Glass. Designed to work with argon/YAG Lasers....
Medicine Products: